

# Bartholomeus Jf Van Den Bemt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6492183/publications.pdf>

Version: 2024-02-01

123  
papers

3,298  
citations

172207

29  
h-index

189595

50  
g-index

125  
all docs

125  
docs citations

125  
times ranked

4034  
citing authors

#	ARTICLE	IF	CITATIONS
1	Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 337-351.	1.3	240
2	Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. <i>Arthritis and Rheumatology</i> , 2018, 70, 60-68.	2.9	142
3	Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. <i>BMJ</i> , The, 2015, 350, h1389-h1389.	3.0	135
4	Prevalence and Preventability of Drug-Related Hospital Readmissions: A Systematic Review. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 602-608.	1.3	135
5	Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2009, 36, 2164-2170.	1.0	120
6	Patient-centred care in established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 643-663.	1.4	99
7	Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar <sc>SB</sc>. <i>Arthritis and Rheumatology</i> , 2018, 70, 1408-1418.	2.9	90
8	Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1849-1854.	0.5	88
9	Identifying the Optimal Role for Pharmacists in Care Transitions: A Systematic Review. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 614-638.	0.5	84
10	The accuracy, precision and sustainability of different techniques for tablet subdivision: Breaking by hand and the use of tablet splitters or a kitchen knife. <i>International Journal of Pharmaceutics</i> , 2014, 466, 44-51.	2.6	73
11	Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. <i>The Cochrane Library</i> , 2014, , CD010455.	1.5	61
12	A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. <i>Drug Delivery</i> , 2019, 26, 384-392.	2.5	60
13	Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. <i>Arthritis Research and Therapy</i> , 2015, 17, 281.	1.6	58
14	Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: A randomized controlled trial. <i>Patient Education and Counseling</i> , 2014, 94, 356-361.	1.0	55
15	The effect of electronic monitoring feedback on medication adherence and clinical outcomes: A systematic review. <i>PLoS ONE</i> , 2017, 12, e0185453.	1.1	55
16	The effect of a pharmacy-led transitional care program on medication-related problems post-discharge: A before-After prospective study. <i>PLoS ONE</i> , 2019, 14, e0213593.	1.1	50
17	Effect of Interactive eHealth Interventions on Improving Medication Adherence in Adults With Long-Term Medication: Systematic Review. <i>Journal of Medical Internet Research</i> , 2021, 23, e18901.	2.1	50
18	Matching Adherence Interventions to Patient Determinants Using the Theoretical Domains Framework. <i>Frontiers in Pharmacology</i> , 2016, 7, 429.	1.6	47

#	ARTICLE	IF	CITATIONS
19	Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1697-1701.	0.5	46
20	Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2014, 8, 1635.	0.8	46
21	Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1939-1944.	0.5	46
22	The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. <i>Rheumatology</i> , 2016, 55, 704-709.	0.9	45
23	Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. <i>Rheumatology</i> , 2010, 49, 1801-1803.	0.9	44
24	Barriers and facilitators with medication use during the transition from hospital to home: a qualitative study among patients. <i>BMC Health Services Research</i> , 2019, 19, 204.	0.9	41
25	Dual-tasking interferes with obstacle avoidance reactions in healthy seniors. <i>Gait and Posture</i> , 2012, 36, 236-240.	0.6	39
26	Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 299.	0.8	39
27	How can we improve adherence to therapy by patients with rheumatoid arthritis?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 681-681.	3.2	37
28	NSAIDs and the Risk of Accidental Falls in the Elderly. <i>Drug Safety</i> , 2009, 32, 489-498.	1.4	37
29	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 12.	0.8	35
30	The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non)response to infliximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 939-945.	1.1	32
31	Pharmacists' Activities to Reduce Medication Waste: An International Survey. <i>Pharmacy (Basel)</i> 11(1): 1-14. <small>0.784314</small> <small>rgBT / Overl</small> <small>0,6</small> <small>32</small>	0.6	32
32	Performance of idarucizumab as antidote of dabigatran in daily clinical practice. <i>Europace</i> , 2019, 21, 414-420.	0.7	31
33	Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists. <i>BMC Cancer</i> , 2017, 17, 122.	1.1	30
34	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 707-713.	0.5	30
35	Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?. <i>PLoS ONE</i> , 2017, 12, e0171070.	1.1	30
36	Making the rheumatologist aware of patients' non-adherence does not improve medication adherence in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 192-196.	0.6	29

#	ARTICLE	IF	CITATIONS
37	Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 170-175.	0.5	29
38	Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 442.	0.8	28
39	Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients. <i>Rheumatology</i> , 2016, 55, 1812-1819.	0.9	27
40	Redispensing of medicines unused by patients: a qualitative study among stakeholders. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 196-204.	1.0	27
41	Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. <i>Acta Anaesthesiologica Scandinavica</i> , 2017, 61, 338-345.	0.7	27
42	Medication-Related Hospital Readmissions Within 30 Days of Discharge: Prevalence, Preventability, Type of Medication Errors and Risk Factors. <i>Frontiers in Pharmacology</i> , 2021, 12, 567424.	1.6	26
43	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 184.	0.8	25
44	Psychosocial predictors of non-adherence to chronic medication: systematic review of longitudinal studies. <i>Patient Preference and Adherence</i> , 2014, 8, 519.	0.8	24
45	Severity of Diabetes Mellitus and Total Hip or Knee Replacement. <i>Medicine (United States)</i> , 2016, 95, e3739.	0.4	24
46	Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. <i>Trials</i> , 2018, 19, 204.	0.7	23
47	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. <i>RMD Open</i> , 2020, 6, e001432.	1.8	23
48	Safety and efficacy of new oral anticoagulants and low molecular weight heparins compared with aspirin in patients undergoing total knee and hip replacements. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1245-1252.	0.9	22
49	Willingness of patients to use unused medication returned to the pharmacy by another patient: a cross-sectional survey. <i>BMJ Open</i> , 2019, 9, e024767.	0.8	22
50	Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 100-105.	1.5	22
51	Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1321-1327.	1.1	21
52	Interventions to support shared decision making for medication therapy in long term conditions: A systematic review. <i>Patient Education and Counseling</i> , 2020, 103, 254-265.	1.0	21
53	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. <i>Drug Safety</i> , 2020, 43, 917-925.	1.4	20
54	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 349-358.	0.8	19

#	ARTICLE	IF	CITATIONS
55	Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. <i>Lancet Rheumatology</i> , The, 2019, 1, e145-e153.	2.2	19
56	Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique. <i>Arthritis Care and Research</i> , 2020, 72, 1410-1419.	1.5	19
57	Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: A cross-sectional study in patients with atrial fibrillation. <i>Patient Education and Counseling</i> , 2021, 104, 155-162.	1.0	19
58	Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in the Netherlands. <i>Current Medical Research and Opinion</i> , 2009, 25, 195-204.	0.9	18
59	Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control study. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 370-378.	1.1	18
60	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 403.	0.7	18
61	Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts. <i>Current Opinion in Rheumatology</i> , 2018, 30, 266-275.	2.0	18
62	Unraveling the Association Between SSRI Use and Falls. <i>Clinical Neuropharmacology</i> , 2011, 34, 210-215.	0.2	17
63	Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. <i>Patient Education and Counseling</i> , 2012, 89, 143-151.	1.0	17
64	Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 843-857.	1.5	17
65	What does it cost to redispense unused medications in the pharmacy? A micro-costing study. <i>BMC Health Services Research</i> , 2019, 19, 243.	0.9	17
66	Validity of a nationwide medication record system in the Netherlands. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 687-690.	1.0	17
67	Disentangling Rheumatoid Arthritis Patients'™ Implicit and Explicit Attitudes toward Methotrexate. <i>Frontiers in Pharmacology</i> , 2016, 7, 233.	1.6	16
68	Older Patients'™ Compliance with Drug Storage Recommendations. <i>Drugs and Aging</i> , 2018, 35, 233-241.	1.3	16
69	&lt;p&gt;Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1199-1211.	0.8	16
70	Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2260-2261.	0.5	15
71	Diagnostic accuracy of a single-lead portable ECG device for measuring QTc prolongation. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12683.	0.5	15
72	Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 1565-1574.	1.0	15

#	ARTICLE	IF	CITATIONS
73	Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. <i>Rheumatology</i> , 2020, 59, 1253-1261.	0.9	15
74	Economic impact of Patient's Own Medication use during hospitalisation: a multicentre pre-post implementation study. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 1658-1665.	1.0	12
75	A comparison between medication reconciliation by a pharmacy technician and the use of an online personal health record by patients for identifying medication discrepancies in patients' drug lists prior to elective admissions. <i>International Journal of Medical Informatics</i> , 2021, 147, 104370.	1.6	12
76	COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 880-890.	0.9	11
77	Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study. <i>Clinical Neuropharmacology</i> , 2018, 41, 14-19.	0.2	11
78	A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement and selection of attributes and levels. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1537-1555.	0.8	11
79	Information needs and patient perceptions of the quality of medication information available in hospitals: a mixed method study. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 1396-1404.	1.0	11
80	Impact of Ramadan Intermittent Fasting on the Heart Rate Variability and Cardiovascular Parameters of Patients with Controlled Hypertension. <i>Journal of Nutrition and Metabolism</i> , 2021, 2021, 1-10.	0.7	11
81	The effect of a non-steroidal anti-inflammatory drug on two important predictors for accidental falls: Postural balance and manual reaction time. A randomized, controlled pilot study. <i>Human Movement Science</i> , 2011, 30, 384-395.	0.6	10
82	Beliefs about inhaled corticosteroids: Comparison of community pharmacists, pharmacy technicians and patients with asthma. <i>Journal of Asthma</i> , 2016, 53, 1051-1058.	0.9	9
83	Pharmacokinetics of 400 mg Locally Infiltrated Ropivacaine After Total Knee Arthroplasty Without Perioperative Tourniquet Use. <i>Regional Anesthesia and Pain Medicine</i> , 2018, 43, 1.	1.1	9
84	Medication management issues identified during home medication reviews for ambulatory community pharmacy patients. <i>Canadian Pharmacists Journal</i> , 2019, 152, 334-342.	0.4	9
85	The development of a test battery to assess the hand-eye functions relevant in predicting easy and accurate tablet subdivision in older people: A pilot study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1969-1981.	1.1	9
86	Adherence to oral anticancer agents: Healthcare providers' perceptions, beliefs and shared decision making in Belgium and the Netherlands. <i>Acta Oncologica</i> , 2016, 55, 437-443.	0.8	8
87	Creating an Interprofessional guideline to support patients receiving oral anticoagulation therapy: a Delphi exercise. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 1012-1020.	1.0	7
88	Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab. <i>Rheumatology</i> , 2022, 61, 3974-3980.	0.9	7
89	The Association Between $\beta$ -Blocker Use and Cardiorespiratory Fitness: The Maastricht Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 37-45.	1.0	6
90	Effect of Ramadan fasting on heart rate variability as a measure of cardiac stress in a Lebanese cohort. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 1237-1239.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Impact of Fasting on Cardiovascular Outcomes in Patients With Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 481-495.	0.8	6
92	<scp>CNS</scp> effects of indomethacin: should patients be cautioned about decreased mental alertness and motor coordination?. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 814-821.	1.1	5
93	Association between healthcare practitioners' beliefs about statins and patients' beliefs and adherence. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1082-1088.	1.1	5
94	Antidrug antibodies to tumour necrosis factor specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective; comment on the article by Vincent <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e14-e14.	0.5	4
95	Redispensing of unused HIV post-exposure prophylaxis for medical students. <i>Travel Medicine and Infectious Disease</i> , 2019, 29, 82-83.	1.5	4
96	Patientsâ€™ and providersâ€™ perspectives on medication relatedness and potential preventability of hospital readmissions within 30 days of discharge. <i>Health Expectations</i> , 2020, 23, 212-219.	1.1	4
97	Electronic Monitoring Feedback for Improving Medication Adherence and Clinical Outcomes in Early Rheumatoid Arthritis: A Randomized Clinical Trial. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1107-1119.	0.8	4
98	Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1985.	1.0	4
99	Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	4
100	InforMatrixÂ®: treatment of rheumatoid arthritis using biologicals. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1769-1789.	0.9	3
101	Are Health Care Professionalsâ€™ Implicit and Explicit Attitudes Toward Conventional Disease-Modifying Antirheumatic Drugs Associated With Those of Their Patients?. <i>Arthritis Care and Research</i> , 2021, 73, 364-373.	1.5	3
102	The effect of a transitional pharmaceutical care program on the occurrence of ADEs after discharge from hospital in patients with polypharmacy. <i>Research in Social and Administrative Pharmacy</i> , 2021, 18, 2651-2651.	1.5	3
103	Rheumatologistsâ€™ beliefs about medication barely differ from patientsâ€™ medication beliefs. <i>European Journal for Person Centered Healthcare</i> , 2017, 5, 308.	0.3	3
104	Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial. <i>RMD Open</i> , 2022, 8, e001712.	1.8	3
105	Identification of antithrombotic drugs related to total joint replacement using anonymised free-text notes: a search strategy in the Clinical Practice Research Datalink. <i>BMJ Open</i> , 2015, 5, e009017.	0.8	2
106	Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 240-248.	1.1	2
107	Stakeholdersâ€™ perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1521-1528.	1.0	2
108	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. <i>Journal of Rheumatology</i> , 2021, 48, 1388-1394.	1.0	2

#	ARTICLE	IF	CITATIONS
109	A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping. JMIR Serious Games, 2022, 10, e31570.	1.7	2
110	Implementation of a pharmacist-led transitional pharmaceutical care programme: Process evaluation of Medication Actions to Reduce hospital admissions through a collaboration between Community and Hospital pharmacists (MARCH). Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 1049-1069.	0.7	2
111	The effect of Patient's Own Medication use on patient's self-reported medication knowledge during hospitalisation: a pre-post intervention study. BMC Health Services Research, 2022, 22, 423.	0.9	2
112	Barriers and facilitators for the usage of a personal health record for medication reconciliation: a qualitative study among patients. British Journal of Clinical Pharmacology, 2022, , .	1.1	2
113	Comment on 'Ami et al' titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'. Annals of the Rheumatic Diseases, 2018, 77, e67-e67.	0.5	1
114	Drug utilization in the Maastricht Study. Medicine (United States), 2020, 99, e18524.	0.4	1
115	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. Trials, 2021, 22, 406.	0.7	1
116	Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time. British Journal of Clinical Pharmacology, 2021, , .	1.1	1
117	Application of intervention mapping to develop and evaluate a pharmaceutical discharge letter to improve information transfer between hospital and community pharmacists. Research in Social and Administrative Pharmacy, 2021, , .	1.5	1
118	Authors' response to the letter from Kalleian Eserian et al. International Journal of Pharmaceutics, 2015, 478, 682-683.	2.6	0
119	Use of parenteral glucocorticoids and the risk of new onset type 2 diabetes mellitus: A case-control study. Diabetes Research and Clinical Practice, 2018, 139, 100-106.	1.1	0
120	FRI0097...RA PATIENTS' PERSPECTIVES ON BIOLOGICAL DMARD-INDUCED ADVERSE DRUG REACTIONS AND THEIR BURDEN. , 2019, , .		0
121	LB0010...ULTRA-LOW DOSES OF RITUXIMAB OR RETREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL. , 2019, , .		0
122	SPO038...FACTORS IMPORTANT FOR MEDICAL ADHERENCE. , 2019, , .		0
123	Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study. Journal of Rheumatology, 2021, 48, 1480-1487.	1.0	0